A groundbreaking cancer therapy utilizing genetically engineered immune cells, known as CAR T-cells, has achieved an unprecedented milestone by keeping a patient free from a potentially deadly nerve tumor for an astonishing 18 years.
This remarkable case represents the longest documented complete remission in a patient treated with CAR T-cell therapy. Medical experts acknowledge this achievement as a significant breakthrough in cancer treatment. “This patient is cured,” stated a leading specialist in oncology.
CAR T-cell therapy has previously been deployed to combat certain blood cancers, such as leukemia. The process involves extracting a patient’s T-cells from their blood, genetically modifying them to specifically target and eliminate cancer cells, and then reinfusing the genetically altered cells back into the patient’s body. A follow-up study in 2022 showcased this therapy’s success by achieving remission in two leukemia patients for approximately 11 years, marking a record achievement at that time.
Historically, CAR T-cell therapy has struggled against solid tumors, such as neuroblastoma, which primarily affects developing nerve cells in young children. These tumors tend to be particularly resistant to immune system attacks, significantly reducing the efficacy of the modified T-cells.
However, researchers were astounded to discover that a patient treated during a CAR T-cell therapy trial in 2005 for childhood neuroblastoma has remained cancer-free for more than 18 years. “These results were amazing – to get complete responses in neuroblastomas with this approach is quite unusual,” remarked a researcher involved in the study.
The treatment was administered to the patient at the age of four after multiple rounds of chemotherapy and radiotherapy had proven ineffective. In the trial, ten additional participants who experienced relapses after conventional treatment were also treated. Remarkably, these patients reported minimal side effects. One participant remained cancer-free for nearly nine years before exiting the study, while the remaining participants succumbed to their cancer within a few years.
The reasons for the varying responses among participants remain elusive. “That’s the $1 million question; we really don’t know why,” said the researcher. Potential factors influencing the divergent outcomes include genetic differences in individual T-cells, as well as lifestyle factors such as diet and prior exposure to infections. The team observed that CAR T-cells persisted longer in the blood of individuals who experienced extended survival.
Another contributing factor may relate to the immunosuppressive nature of some tumors, which could effectively resist the action of CAR T-cells more robustly than others.
Researchers are now investigating novel methods to enhance the efficacy of CAR T-cells, aiming to improve their potency while minimizing potential toxicities. This pursuit holds promise for expanding the benefits of CAR T-cell therapy to more patients in the future, showcasing a hopeful perspective on the treatment’s potential. “Now we’ve seen a glimpse of what is feasible,” said a leading expert in the field.
Topics:
